A once-daily pill related to Viagra slowed clinical decline by 31% over a year in some people with early Alzheimer’s disease, in a global Phase 3 trial whose results were presented on Monday at the Clinical Trials on Alzheimer’s Disease conference in Boston.
The drug, AR1001, is made by the South Korean biotechnology company AriBio. Its active ingredient, mirodenafil, belongs to the same class of medicines as sildenafil, the compound in Viagra, and is thought to work by improving blood flow to the brain. Unlike the approved Alzheimer’s drugs lecanemab and donanemab, which clear amyloid plaques from the brain, AR1001 targets blood flow instead.
The POLARIS-AD trial enrolled 1,535 people with early Alzheimer’s disease across about 230 sites in 13 countries, including the United Kingdom, the United States, South Korea, China and Canada. Participants were randomly assigned to take 30 mg of AR1001 or a placebo once a day for 52 weeks. Decline was measured on the Clinical Dementia Rating–Sum of Boxes, an 18-point scale covering memory, judgment and the ability to carry out everyday activities.
The headline result applied only to a prespecified subgroup of 604 patients who were not taking any other dementia medicine when the trial began. In that group, those on AR1001 declined 0.44 points less than those on placebo, a difference the company described as a 31% slowing of decline — roughly equivalent to delaying progression by three and a half months over a year. The result was statistically significant, at p=0.0266.
Across all 1,535 participants, however, the picture was very different. The difference between drug and placebo was just 0.11 points, with a p-value of 0.4015 — not statistically significant, and equivalent to about 7% slowing. The trial had been designed so that success in either the overall group or the monotherapy group would count as meeting its primary endpoint, so AriBio says the trial met its goal. But the gap between the two results is the central question now facing the drug.
Independent experts urged caution. Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, called the results encouraging and said side effects were mostly mild to moderate. Dr Sheona Scales, director of research at Alzheimer’s Research UK, noted that the benefit was not significant across the overall trial group. Professor Tara Spires-Jones, a neurodegeneration researcher at the University of Edinburgh, described the findings as “very promising” — while all three stressed that further trials and regulatory scrutiny are needed before the drug could be prescribed.
On safety, serious adverse events occurred in 10.0% of patients on AR1001 and 9.8% of those on placebo. More patients stopped treatment because of side effects on the drug than on placebo — 5.2% against 1.7% — and deaths were reported in 0.5% of the AR1001 group and 0.3% of the placebo group, with causes not given. AriBio says it plans to discuss the complete findings with the US Food and Drug Administration; it has given no filing date, and the drug is not approved anywhere for Alzheimer’s disease. Shares in AriBio fell by almost 30% on Monday after the results were released.
Experts also stressed that AR1001 is not Viagra, and that people should not take Viagra in an attempt to treat Alzheimer’s disease.
These are topline results announced by the company and presented at a conference; they have not yet been published in a peer-reviewed journal, and the headline 31% figure applies only to the subgroup of patients who were not taking other dementia drugs.
Sources: AriBio, “AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial” — https://www.globenewswire.com/news-release/2026/11/17/3404242/0/en/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial.html ; Seoul Economic Daily, “Aribio’s Oral Alzheimer’s Drug Shows Partial Effect in Phase 3” — https://en.sedaily.com/business/2026/11/17/aribios-oral-alzheimers-drug-shows-partial-effect-in-phase-3
